Galunisertib

Drug Profile

Galunisertib

Alternative Names: LY-2157299

Latest Information Update: 08 Dec 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer AstraZeneca; Eli Lilly; National Cancer Institute (USA); Vanderbilt-Ingram Cancer Center; Weill Cornell Medical College
  • Class Antineoplastics; Pyrazoles; Pyridines; Pyrroles; Quinolines; Small molecules
  • Mechanism of Action Phosphotransferase inhibitors; Transforming growth factor beta1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Myelodysplastic syndromes
  • Phase II Breast cancer; Glioblastoma; Hepatocellular carcinoma; Pancreatic cancer
  • Phase I/II Glioma; Non-small cell lung cancer
  • Phase I Cancer; Solid tumours

Most Recent Events

  • 01 Dec 2016 Eli Lilly plans a phase II trial for Pancreatic cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA, United Kingdom, Argentina, Australia, Belgium, Brazil, France, Hungary, Israel, Spain and Taiwan (PO) (NCT02981342)
  • 10 Oct 2016 Eli Lilly completes a phase I trial in Cancer (Late-stage disease, Second-line therapy or greater) in USA (NCT02304419)
  • 15 Sep 2016 Abramson Cancer Center of the University of Pennsylvania plans a phase I trial for Hepatocellular carcinoma (Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (PO) (NCT02906397)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top